Literature DB >> 11520057

Involvement of ERK and protein tyrosine phosphatase signaling pathways in EGCG-induced cyclooxygenase-2 expression in Raw 264.7 cells.

J W Park1, Y J Choi, S I Suh, T K Kwon.   

Abstract

Prostaglandins play regulatory roles in a variety of physiological and pathological processes in immune response and inflammation. Epigallocatechin-3-gallate (EGCG) is known to potent antitumor agent with antioxidant property. We first investigated the effect of EGCG on the production of prostaglandin E(2) (PGE(2)) and the expression of cyclooxygenase-2 (COX-2), the rate-limiting enzyme in the synthesis of PGE(2), using macrophage cell line, Raw264.7. Our results showed that COX-2 expression and PGE(2) production are upregulated by EGCG treatment and that this induction of COX-2 is regulated in part at the transcriptional level. In addition, we demonstrated the signal transduction pathway of mitogen-activated protein kinase (MAP kinase) in EGCG-mediated COX-2 expression. The MEK inhibitor (PD098059) prevented EGCG-induced COX-2 expression, whereas sodium orthovanadate (protein-tyrosine phosphatase inhibitor) significantly enhanced COX-2 expression and PGE(2) production. These results suggest that EGCG mediated COX-2 expression and PGE(2) production is associated with the activation of both the ERK and protein-tyrosine phosphatase signaling pathways. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520057     DOI: 10.1006/bbrc.2001.5415

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Molecular and cellular targets.

Authors:  Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-06       Impact factor: 4.784

Review 2.  Induction of cellular and molecular immunomodulatory pathways by vitamin A and flavonoids.

Authors:  Sapna Patel; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2015-07-17       Impact factor: 4.388

3.  EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP.

Authors:  Jamie Winderbaum Fernandez; Kavon Rezai-Zadeh; Demian Obregon; Jun Tan
Journal:  FEBS Lett       Date:  2010-09-17       Impact factor: 4.124

4.  Anti-inflammatory activity of soy and tea in prostate cancer prevention.

Authors:  Anna Hsu; Tammy M Bray; Emily Ho
Journal:  Exp Biol Med (Maywood)       Date:  2010-06

5.  Antinociceptive effects of dezocine on complete Freund's adjuvant-induced inflammatory pain in rats.

Authors:  Zhenhai Ye; Maoxian Zhang; Ning Ding; Peng Gao; Yunpeng Hei; Yun Wang; Wei Gao; Qingshan Ye
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

6.  Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin-15 but not interleukin-1β responses.

Authors:  Sapna Patel; Archana Akalkotkar; Joseph J Bivona; Ji-Young Lee; Young-Ki Park; Mingke Yu; Sara L Colpitts; Michael Vajdy
Journal:  Immunology       Date:  2016-06-22       Impact factor: 7.397

7.  COX-2 is essential for EGF induction of cell proliferation in gastric RGM1 cells.

Authors:  Eiji Sasaki; Kazunari Tominaga; Toshio Watanabe; Yasuhiro Fujiwara; Nobuhide Oshitani; Takayuki Matsumoto; Kazuhide Higuchi; A S Tarnawski; Tetsuo Arakawa
Journal:  Dig Dis Sci       Date:  2003-12       Impact factor: 3.199

8.  Chemoprevention of prostate cancer: soy isoflavones and curcumin.

Authors:  Shigeo Horie
Journal:  Korean J Urol       Date:  2012-10-19

9.  Association between Gαi2 and ELMO1/Dock180 connects chemokine signalling with Rac activation and metastasis.

Authors:  Hongyan Li; Lei Yang; Hui Fu; Jianshe Yan; Ying Wang; Hua Guo; Xishan Hao; Xuehua Xu; Tian Jin; Ning Zhang
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Transcutaneous electrical nerve stimulation attenuates CFA-induced hyperalgesia and inhibits spinal ERK1/2-COX-2 pathway activation in rats.

Authors:  Jun-Fan Fang; Yi Liang; Jun-Ying Du; Jian-Qiao Fang
Journal:  BMC Complement Altern Med       Date:  2013-06-15       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.